Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

A study, published Sunday in the New England ... the maker of Wegovy and Ozempic, said both Wegovy and Zepbound have demonstrated clinically significant weight reduction in clinical trial programs.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.